- Home
- BYAH vs OSRH Comparison
BYAH vs OSRH Comparison
Compare BYAH & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYAH | OSRH |
|---|---|---|
| Founded | 2016 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | BYAH | OSRH |
|---|---|---|
| Price | $0.21 | $0.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 230.5K | ★ 10.2M |
| Earning Date | 08-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,768,120.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.65 | N/A |
| 52 Week Low | $0.20 | $0.45 |
| 52 Week High | $41.49 | $12.54 |
Technical Indicators
Market Signals| Indicator | BYAH | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.48 |
| Support Level | N/A | $0.63 |
| Resistance Level | N/A | $0.77 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.